Cargando…

Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients

BACKGROUND: There is a deep need to improve the care of metastatic breast cancer (MBC) patients, since even today it remains an incurable disease. Taxanes are considered the most effective cytotoxic drugs for the treatment of MBC, both in monotherapy and in combined schedules, but the need for synth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fabi, Alessandra, Giannarelli, Diana, Malaguti, Paola, Ferretti, Gianluigi, Vari, Sabrina, Papaldo, Paola, Nisticò, Cecilia, Caterino, Mauro, De Vita, Roy, Mottolese, Marcella, Iacorossi, Laura, Cognetti, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662373/ https://www.ncbi.nlm.nih.gov/pubmed/26640370 http://dx.doi.org/10.2147/DDDT.S89575

Ejemplares similares

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
por: Fabi, Alessandra, et al.
Publicado: (2012)

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials
por: Cuppone, Federica, et al.
Publicado: (2011)

First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?
por: Fabi, Alessandra, et al.
Publicado: (2016)

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
por: Palumbo, Raffaella, et al.
Publicado: (2015)

Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: A meta-analysis
por: Lee, Hwaryeon, et al.
Publicado: (2020)

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study
por: Lazzaro, Carlo, et al.
Publicado: (2013)

Nanoparticle albumin-bound paclitaxel in a patient with locally advanced breast cancer and taxane-induced skin toxicity: a case report
por: Cirauqui, Beatriz Cirauqui, et al.
Publicado: (2014)

Clinical experience with nanoparticle albumin-bound paclitaxel, a novel taxane anticancer agent, and management of adverse events in females with breast cancer
por: TAKASHIMA, SEIKI, et al.
Publicado: (2015)

Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials
por: Rossi, Valentina, et al.
Publicado: (2019)

Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas
por: Tian, Zhichao, et al.
Publicado: (2022)

Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma
por: Hassan, Md Sazzad, et al.
Publicado: (2018)

Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
por: He, Fei, et al.
Publicado: (2021)

Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration
por: Chen, Nianhang, et al.
Publicado: (2015)

Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer
por: Di Costanzo, Francesco, et al.
Publicado: (2009)

Albumin-bound paclitaxel in solid tumors: clinical development and future directions
por: Kundranda, Madappa N, et al.
Publicado: (2015)

Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Gelatin Methacryloyl Hydrogels Control the Localized Delivery of Albumin-Bound Paclitaxel
por: Vigata, Margaux, et al.
Publicado: (2020)

Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma
por: Takahashi, Akiko, et al.
Publicado: (2022)

Delivering albumin-bound paclitaxel across the blood-brain barrier for gliomas
por: Gould, Andrew, et al.
Publicado: (2021)

The immersive experience of virtual reality during chemotherapy in patients with early breast and ovarian cancers: The patient’s dream study
por: Fabi, Alessandra, et al.
Publicado: (2022)

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials
por: Ferretti, G, et al.
Publicado: (2006)

Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer
por: Gori, S, et al.
Publicado: (2004)

Albumin-bound formulation of paclitaxel (Abraxane(®) ABI-007) in the treatment of breast cancer
por: Miele, Evelina, et al.
Publicado: (2009)

Repetitive responses to nanoparticle albumin‐bound paclitaxel and carboplatin in malignant pleural mesothelioma
por: Kanai, Osamu, et al.
Publicado: (2016)

Superior Antitumor Activity of Nanoparticle Albumin-Bound Paclitaxel in Experimental Gastric Cancer
por: Zhang, Changhua, et al.
Publicado: (2013)

Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients
por: Li, Qingmei, et al.
Publicado: (2018)

Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions
por: Giordano, Guido, et al.
Publicado: (2017)

Albumin-bound paclitaxel as new treatment for metastatic cholangiocarcinoma: A case report
por: Martin Huertas, Roberto, et al.
Publicado: (2020)

Weekly nanoparticle albumin-bound paclitaxel and paclitaxel for relapsed small cell lung cancer: A retrospective observational study
por: Oi, Hajime, et al.
Publicado: (2022)

Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?
por: Cucinotto, Iole, et al.
Publicado: (2013)

nab-Paclitaxel (Abraxane(®)): an albumin-bound cytotoxic exploiting natural delivery mechanisms into tumors
por: Iglesias, J
Publicado: (2009)

A Retrospective Study of Efficacy and Safety of Albumin-Bound Paclitaxel in Metastatic Breast Cancer
por: Singh, Rajesh Kumar, et al.
Publicado: (2014)

Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells
por: Vallo, Stefan, et al.
Publicado: (2017)

Ultra-widefield angiographic imaging of albumin-bound paclitaxel-induced cystoid macular edema
por: Lee, Junhyuck, et al.
Publicado: (2019)

MRI-guided microwave ablation and albumin-bound paclitaxel for lung tumors: Initial experience
por: Shen, Xiaokang, et al.
Publicado: (2022)

Low Intensity Ultrasound as an Antidote to Taxane/Paclitaxel-induced Cytotoxicity
por: Amaya, Celina, et al.
Publicado: (2022)

AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations
por: Falcone, Italia, et al.
Publicado: (2020)

Safety of nanoparticle albumin-bound paclitaxel administered to breast cancer patients with clinical contraindications to paclitaxel or docetaxel: Four case reports
por: KIMURA, KOSEI, et al.
Publicado: (2013)

Nanoparticle albumin-bound paclitaxel versus solvent-based paclitaxel in breast cancer: A protocol for systemic review and meta-analysis
por: Li, Bingxue, et al.
Publicado: (2021)

Macrophage Polarization Contributes to the Anti-Tumoral Efficacy of Mesoporous Nanovectors Loaded with Albumin-Bound Paclitaxel
por: Leonard, Fransisca, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1nsmqrm286aqhe57sg1r7cpvfe